Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating)'s share price rose 7% during trading on Thursday . The stock traded as high as $1.57 and last traded at $1.53. Approximately 200,841 shares were traded during mid-day trading, an increase of 50% from the average daily volume of 133,473 shares. The stock had previously closed at $1.43.
Wall Street Analysts Forecast Growth
TALS has been the subject of several recent research reports. Evercore ISI lifted their target price on shares of Talaris Therapeutics to $20.00 in a report on Monday, August 15th. HC Wainwright started coverage on shares of Talaris Therapeutics in a report on Thursday, October 20th. They issued a "buy" rating and a $18.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on shares of Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, September 9th.
Get Talaris Therapeutics alerts:Talaris Therapeutics Stock Performance
The stock has a market capitalization of $63.80 million, a PE ratio of -1.01 and a beta of 1.94. The stock's 50 day moving average is $2.53 and its two-hundred day moving average is $4.62.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last announced its earnings results on Monday, August 15th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Equities research analysts expect that Talaris Therapeutics, Inc. will post -1.85 EPS for the current fiscal year.Insider Activity at Talaris Therapeutics
In other news, insider Suzanne Ildstad sold 525,000 shares of the company's stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $2.80, for a total value of $1,470,000.00. Following the completion of the sale, the insider now directly owns 3,081,446 shares in the company, valued at $8,628,048.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in TALS. Bank of Montreal Can increased its stake in Talaris Therapeutics by 1,388.6% during the third quarter. Bank of Montreal Can now owns 334,061 shares of the company's stock worth $1,193,000 after acquiring an additional 311,619 shares during the last quarter. State Street Corp increased its position in shares of Talaris Therapeutics by 40.6% during the 1st quarter. State Street Corp now owns 261,465 shares of the company's stock worth $2,573,000 after purchasing an additional 75,463 shares during the last quarter. BlackRock Inc. raised its holdings in Talaris Therapeutics by 1.6% in the 1st quarter. BlackRock Inc. now owns 2,433,914 shares of the company's stock valued at $23,950,000 after buying an additional 38,449 shares during the period. Nicholas Investment Partners LP acquired a new position in Talaris Therapeutics in the first quarter valued at about $221,000. Finally, Rhumbline Advisers lifted its position in Talaris Therapeutics by 112.3% in the second quarter. Rhumbline Advisers now owns 31,713 shares of the company's stock valued at $143,000 after buying an additional 16,772 shares during the last quarter. 67.99% of the stock is currently owned by institutional investors and hedge funds.
About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Articles
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Coupang Stock And Why You Should Care
- This Is No Time To Buy D.R. Horton Stock
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.